A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This literature review assessed the burden of treatment-resistant depression in the United States by compiling published data about the clinical, societal, and economic outcomes associated with failure to respond to one or more adequate trials of drug therapy. METHODS: PubMed and the Tufts Cost-Effectiveness Analyses Registry were searched for English-language articles published between January 1996 and August 2013 that collected primary data about treatment-resistant depression. Two researchers independently assessed study quality and extracted data. RESULTS: Sixty-two articles were included (N=59,462 patients). Patients with treatment-resistant depression had 3.8±2.1 prior depressive episodes and illness duration of 4.4±3.3 years and had completed 4.7±2.7 unsuccessful drug trials involving 2.1±.3 drug classes. Response rates for treatment-resistant depression were 36%±1%. A total of 17%±6% of patients had prior suicide attempts (1.1±.2 attempts per patient). Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response. Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression. CONCLUSIONS: Treatment-resistant depression exacts a substantial toll on patients' quality of life. At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion. These findings underscore the need for research on the mechanisms of depression, new therapeutic targets, existing and new treatment combinations, and tests to improve the efficacy of and adherence to treatments for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As many as 30% of patients with MDD do not adequately respond to two therapies and are considered to be treatment resistant.”
In the citing paper
“Among private payers, the mean annual direct healthcare costs per patient for the management of TRD (US$13,196; 2013 GBP8437) were higher than for management of treatment-responsive depression (US$7715; 2013 GBP4933) 14”
In the citing paper
“These cardiovascular effects may complicate treatment of patients with TRD who, in real-world settings, often have hypertension (67%) and cardiovascular disease (56%) [15].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [15]
In the citing paper
“the mean quality of life is estimated to be 20% lower in TRS compared with non-TRS. 41 Mean quality of life is approximately 25-40% lower in patients with TRD compared with patients who respond to treatment or who are in remission; 46”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [46]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Childhood and adolescent depression: a review of the past 10 years, Part I
BIRMAHER, B., RYAN, N. D., WILLIAMSON, D. E., BRENT, D. A., KAUFMAN, J., DAHL, R. E., PEREL, J., & NELSON, B. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199611000-00011 · Cited by 2,076
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Williams, D. R., González, H. M., Neighbors, H., Nesse, R., Abelson, J. M., Sweetman, J., & Jackson, J. S. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.305 · Cited by 1,293
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression
Lozano, A. M., Mayberg, H. S., Giacobbe, P., Hamani, C., Craddock, R. C., & Kennedy, S. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.034 · Cited by 1,024
Research works printed but not linked: 3
- Nierenberg AA, 2001, Journal of Clinical Psychiatry, 62, 5
- Thase ME, 1997, Journal of Clinical Psychiatry, 58, 23
- 1976, Clinical Global Impression (CGI)
Cited by
Items 101–200 of 576
Mahlich, J., Tsukazawa, S., & Wiegand, F. (2018) · Drugs - Real World Outcomes · doi:10.1007/s40801-017-0126-5 · Cited by 49
Humanistic and Economic Burden of Conversion Therapy Among LGBTQ Youths in the United States
Forsythe, A., Pick, C. J., Tremblay, G., Malaviya, S., Green, A. C., & Sandman, K. E. (2022) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2022.0042 · Cited by 59
The History and Future of Ablative Neurosurgery for Major Depressive Disorder
Volpini, M., Giacobbe, P., Cosgrove, G. R., LEVITT, A. J., Lozano, A. M., & Lipsman, N. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000478025 · Cited by 51
Olfson, M., Amos, T. B., Benson, C., McRae, J., & Marcus, S. C. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.3.226 · Cited by 48
“Total health care costs, $ Total 17,997 (34,146) 10,325 (28,224) 6,749 (5,268-8,230) 5,923 (4,409-7,437) Mental health related 4,122 (8,657) 1,869 (6,643) 1,957 (1,586-2,327) 2,015 (1,607-2,423) Depression related 1,969 (4,203) 943 (3,314) 899 (725-1,072) 760 (595-925) Prescription pharmacy costs, $ Total 4,986 (9,529…”
Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder
Groessl, E. J., Tally, S. R., Hillery, N., Maciel, A., & Garces, J. A. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.8.726 · Cited by 55
“However, depending on the definition, treatment-resistant patients comprise a much smaller subset of all people with depression.(12,44,45) Thus, although the per-person benefit of pharmacogenetic-guided treatment may be smaller, this approach to treatment can benefit virtually all people with moderate or severe depres…”
BackgroundMethodInfluentialWang, M., Yang, L., Chen, Z., Dai, L., Xi, C., Wu, X., Wu, G., Wang, Y., & Hu, J. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05895-8 · Cited by 52
Treatment resistant opioid use disorder (TROUD): Definition, rationale, and recommendations
Wolf, D. A. P. S., & Gold, M. S. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116718 · Cited by 50
Li, Z., Zhao, L., Chen, J., Liu, C., Li, S., Mei, H., Qu, D., Shao, Z., & Sun, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.07.098 · Cited by 46
Steer, E. (2019) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2017.08.002 · Cited by 57
Kim, N., Cho, S., Kim, H.-Y., Kim, S. H., Lee, H. J., Park, C. H. K., Rhee, S. J., Kim, D.-W., Yang, B. R., Choi, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221552 · Cited by 48
Regenold, W. T., Noorani, R. J., Piez, D. A., & Patel, P. (2015) · Brain stimulation · doi:10.1016/j.brs.2015.06.011 · Cited by 50
Han, X., Qin, Y., Zhu, Y., Zhang, X., Wang, N.-X., Rang, Y., Zhai, X., & Lu, Y. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.06.043 · Cited by 45
Ng, J., Rosenblat, J. D., Lui, L. M. W., Teopiz, K. M., Lee, Y. L., Lipsitz, O., Mansur, R. B., Rodrigues, N. B., Nasri, F., Gill, H., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.06.032 · Cited by 50
Soares, B. G., KANEVSKY, G. A., Teng, C. T., Pérez‐Esparza, R., Bonetto, G. G., Lacerda, A. L. T., Uribe, E. S., Cordoba, R., Lupo, C., Samora, A. M., et al. (2021) · Psychiatric Quarterly · doi:10.1007/s11126-021-09930-x · Cited by 56
Assessing the Risk Factors for Difficult-to-Treat Depression and Treatment-Resistant Depression
Gaynes, B. N. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14077su1c.01 · Cited by 48
Balbuena, L., Bowen, R., Baetz, M., & Marwaha, S. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00174 · Cited by 51
Monoamine Oxidase Inhibitors—Revisiting a Therapeutic Principle
Entzeroth, M., & Ratty, A. K. (2017) · Open Journal of Depression · doi:10.4236/ojd.2017.62004 · Cited by 47
“An economic study by Mrazek et al. (2014), covering the period between 1996 and 2013, estimated the costs associated with TRD in the US amounted to $29 - 48$ billion.”
BackgroundSerchov, T., Schwarz, I., Theiß, A., Sun, L., Holz, A., Döbrössy, M. D., Schwarz, M. K., Normann, C., Biber, K. P. H., & van Calker, D. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107834 · Cited by 50
A review of effects of calorie restriction and fasting with potential relevance to depression
Igwe, O., Sone, M., Matveychuk, D., Baker, G. B., & Dursun, S. M. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110206 · Cited by 46
The forced swim test has poor accuracy for identifying novel antidepressants
Trunnell, E. R., & Carvalho, C. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.003 · Cited by 52
Increasing Adiponergic System Activity as a Potential Treatment for Depressive Disorders
Formolo, D. A., Lee, T. H.-Y., & Yau, S. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01644-3 · Cited by 42
“This devastating disorder imposes a huge economic burden on patients and the healthcare systems [3, 4].”
BackgroundInfluentialLi, M.-S., Du, X., Chu, H.-C., Liao, Y.-Y., Pan, W. H., Li, Z., & Hung, G. C. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2119-2 · Cited by 46
“They account for more frequent medical visits and higher health care costs [6].”
BackgroundSzwimer, E., Mougharbel, F., Goldfield, G. S., & Alberga, A. S. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00367-0 · Cited by 48
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Kamphuis, J., van Asselt, A. D. I., Touw, D. J., aan het Rot, M., & Schoevers, R. A. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2359-1 · Cited by 39
McAllister, C., Hisler, G. C., Blake, A. B., Twenge, J. M., Farley, E., & Hamilton, J. L. (2021) · Research on Child and Adolescent Psychopathology · doi:10.1007/s10802-021-00832-x · Cited by 38
Oliveira-Maia, A. J., Bobrowska, A., Constant, É., Ito, T., Kambarov, Y., Luedke, H., Mulhern-Haughey, S., & von Holt, C. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02700-0 · Cited by 56
“This is in agreement with an earlier review of studies of patients with TRD, which captured data from nearly 60,000 patients and reported wide-ranging rates of remission and response, averaging 20% and 36%, respectively [11].”
InfluentialThe Economics of Treatment for Depression
Stecher, C. D., Cloonan, S., & Domino, M. E. (2023) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-061022-040533 · Cited by 51
Should Mental Disorders Be a Basis for Physician-Assisted Death?
Appelbaum, P. S. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201700013 · Cited by 37
Brain–computer interfaces for neuropsychiatric disorders
Oganesian, L. L., & Shanechi, M. M. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00177-2 · Cited by 58
Tanner, J., Davies, P. E., Voudouris, N. C., Shahmirian, A., Herbert, D., Braganza, N., Gugila, A., DeChairo, B. M., & Kennedy, J. L. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.012 · Cited by 40
Dysfunction of Glutamatergic Synaptic Transmission in Depression: Focus on AMPA Receptor Trafficking
He, J.-G., Zhou, H.-Y., Wang, F., & Chen, J.-G. (2023) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2022.02.007 · Cited by 36
Use of Ketamine in Elderly Patients with Treatment-Resistant Depression
Ribeiro, C. M. D. F., & Riva‐Posse, P. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0855-x · Cited by 41
Dalhuisen, I., van Bronswijk, S. C., Bors, J., Smit, F., Spijker, J., Tendolkar, I., Ruhé, H. G., & van Eijndhoven, P. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104848 · Cited by 40
“MDD greatly impacts quality of life, and has immense societal and economic consequences (Mrazek et al., 2014).”
Backgroundvan Calker, D., Serchov, T., Normann, C., & Biber, K. P. H. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.014 · Cited by 36
“Major depression is estimated to affect more than 300 million people worldwide and is associated with high individual suffering, increased risk of suicide and an enormous economic burden for the society (Eaton et al., 2008; Mrazek et al., 2014).”
BackgroundFitzgibbon, K. P., Plett, D., Chan, B., Hancock, R., Coyte, P. C., & Blumberger, D. M. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719890167 · Cited by 43
Sahlem, G. L., McCall, W. V., Short, E. B., Rosenquist, P. B., Fox, J. B., Youssef, N. A., Manett, A. J., Kerns, S. E., Dancy, M. M., McCloud, L., et al. (2020) · Brain stimulation · doi:10.1016/j.brs.2020.07.015 · Cited by 38
“469 [5] Mrazek DA, Hornberger JC, Altar CA, Degtiar I.”
BackgroundAssociations between dietary carotenoid intakes and the risk of depressive symptoms
Ge, H., Yang, T., Sun, J., & Zhang, D. (2020) · Food & Nutrition Research · doi:10.29219/fnr.v64.3920 · Cited by 38
“9% in 2015 (2), and the financial burden of depression in the United States was $188 billion in 2012 (3).”
BackgroundInhibition of IL-6 methylation by Saikosaponin C regulates neuroinflammation to alleviate depression
Bai, Z., Gao, T., Zhang, R., Lu, Y., Tian, J., Wang, T., Zhao, K., & Wang, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110043 · Cited by 37
Yan, M., Bo, X., Zhang, J., Liu, S., Li, X., Liao, Y., Liu, Q., Cheng, Y., & Cheng, J. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114426 · Cited by 39
Maintenance Ketamine Therapy for Treatment-Resistant Depression
Archer, S., Chrenek, C., & Swainson, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000894 · Cited by 34
Li, M., Yang, Y., Pang, L., Wu, M., Wang, Z., Fu, Y., & Li, K. (2019) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2019.08.010 · Cited by 34
Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
Fabbri, C., & Serretti, A. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.1.1 · Cited by 44
The economic cost of treatment-resistant depression in patients referred to a specialist service
McCrone, P., Rost, F., Koeser, L., Koutoufa, I., Stephanou, S., Knapp, M., Goldberg, D., Taylor, D., & Fonagy, P. (2018) · Journal of Mental Health · doi:10.1080/09638237.2017.1417562 · Cited by 33
“The economic burden of major depressive disorder (MDD) was estimated at $124 billion in the USA in 2012 (Mrazek et al., 2014) and €118 billion in Europe in 2004 (Richards, 2011).”
Grey Matter changes in treatment-resistant depression during electroconvulsive therapy
Yrondi, A., Nemmi, F., Billoux, S., Giron, A., Sporer, M., Taïb, S., Salles, J., Pierre, D., Thalamas, C., Rigal, É., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.075 · Cited by 35
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Spaans, H.-P., Kamphuis, J., & Schoevers, R. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.123 · Cited by 33
The Way to a Human’s Brain Goes Through Their Stomach: Dietary Factors in Major Depressive Disorder
Aly, J. S., & Engmann, O. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.582853 · Cited by 39
“Notably, chronic supplementation with either, vitamin B9 or vitamin B12, may improve MDD-symptoms particularly in men (Murakami et al., 2008; Gougeon, 2014).”
BackgroundLevy, A., Taïb, S., Arbus, C., Péran, P., Sauvaget, A., Schmitt, L., & Yrondi, A. (2019) · Journal of Ect · doi:10.1097/yct.0000000000000570 · Cited by 39
Advances in novel molecular targets for antidepressants
Wang, Q., & Dwivedi, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110041 · Cited by 34
“In fact, the remission rate for monotherapy with an antidepressant is ~50% and 20–30% of the patients even do not respond to specific antidepressants (Mrazek et al., 2014).”
BackgroundDrug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study
Fabbri, C., Kasper, S., Zohar, J., Souery, D., Montgomery, S., Albani, D., Forloni, G., Ferentinos, P. P., Rujescu, D., Mendlewicz, J., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110050 · Cited by 39
Langhein, M., Seitz‐Holland, J., Lyall, A. E., Pasternak, O., Chunga, N., Karayumak, S. C., Kubicki, A., Mulert, C., Espinoza, R. T., Narr, K. L., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.06.043 · Cited by 34
Are cognitive aspects of defense a core feature of anxiety and depression?
Blanchard, D. C. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104947 · Cited by 32
Optimization of Antidepressant Use with Pharmacogenetic Strategies
Torrellas, C., Carril, J. C., & Cacabelos, R. (2017) · Current Genomics · doi:10.2174/1389202918666170426164940 · Cited by 34
“This assortment of syndromes is made up of clinical pictures which may become markedly severe and thus entail a significant reduction in the quality of life of those affected and their environment [3, 4], an extended use of health service resources [5], considerable economic costs associated with the loss of productiv…”
BackgroundAntidepressant effects of focused ultrasound induced blood-brain-barrier opening
Mooney, S. J., Nóbrega, J. N., LEVITT, A. J., & Hynynen, K. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.01.004 · Cited by 31
Draganov, M., Arranz, M. J., Salazar, J., de Diego-Adeliño, J., Gallego-Fábrega, C., Jubero, M., Carceller‐Sindreu, M., & Portella, M. J. (2019) · European Psychiatry · doi:10.1016/j.eurpsy.2019.05.003 · Cited by 34
“Treatment failure has a negative effect on patients quality of life, is associated with increased risk for suicidal behavior and has higher economic costs for society [4].”
BackgroundTanner, J., Davies, P. E., Overall, C. C., Grima, D. T., Nam, J., & DeChairo, B. M. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0012 · Cited by 31
Treatment-Resistant Depression in Poland—Epidemiology and Treatment
Gałecki, P., Samochowiec, J., Mikułowska, M., & Szulc, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030480 · Cited by 38
Emerging evidence for antidepressant actions of anesthetic agents
Tadler, S. C., & Mickey, B. J. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000617 · Cited by 31
Quan, Z., Li, H., Quan, Z., & Qing, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087098 · Cited by 39
“Not only does depression bring mental problems to the patients themselves, but it also causes financial and social burdens to their families and society [2].”
BackgroundImprovements in Health-Related Quality of Life With Electroconvulsive Therapy: A Meta-analysis
Giacobbe, P., Rakita, U., Penner-Goeke, K., Feffer, K., Flint, A. J., Kennedy, S. H., & Downar, J. H. (2018) · Journal of Ect · doi:10.1097/yct.0000000000000486 · Cited by 34
“At a societal level, the bulk of the burden of MDD is associated with a failure to achieve a full clinical response to antidepressant treatments.(4) Despite a wide variety of available pharmacological strategies to treat MDD,(5) it is estimated that a third of patients with MDD will not achieve full resolution of thei…”
BackgroundCarboni, L., Marchetti, L., Lauria, M., Gass, P., Vollmayr, B., Redfern, A. J., Jones, L., Razzoli, M., Malki, K., Begni, V., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0117-6 · Cited by 32
“INTRODUCTION About one third of major depressive disorder (MDD) patients do not respond or respond only partially to available treatments [1].”
BackgroundTricklebank, M. D., Robbins, T. W., Simmons, C., & Wong, E. H. F. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05787-x · Cited by 33
Sun, Z., Jia, L., Shi, D., He, Y., Ren, Y., Yang, J., & Ma, X. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113709 · Cited by 34
Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date
Ragguett, R.-M., Rong, C., Kratiuk, K., & McIntyre, R. S. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1559295 · Cited by 30
Kanekar, S., Sheth, C. S., Ombach, H. J., Olson, P. R., Bogdanova, O. V., Petersen, M., Renshaw, C. E., Sung, Y., D’Anci, K. E., & Renshaw, P. F. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.05.002 · Cited by 32
“costs, MDD is ranked amongst diseases most debilitating to society (Mrazek et al., 2014).”
Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
Carboni, E., Carta, A. R., Carboni, E., & Novelli, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.657714 · Cited by 35
Gobbi, G., Ghabrash, M. F., Núñez, N. A., Tabaka, J. M., Sante, J. D., Saint-Laurent, M., Vida, S., Kolivakis, T., Low, N. C. P., Cervantes, P., et al. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000196 · Cited by 31
Dougherty, R. F., Clarke, P., Atli, M., Kuc, J., Schlosser, D. A., Dunlop, B. W., Hellerstein, D. J., Aaronson, S. T., Zisook, S., Young, A. H., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06432-5 · Cited by 35
Bian, L.-H., Wang, S., Li, W., Li, J., Yin, Y., Ye, F.-F., & Guo, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115921 · Cited by 32
Alternate healthy eating index and risk of depression: A meta-analysis and systemematic review
Wu, P.-Y., Lin, M., & Tsai, P. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1477424 · Cited by 30
Medicaid spending burden among beneficiaries with treatment-resistant depression
Pilon, D., Sheehan, J. J., Szukis, H., Singer, D., Jacques, P., Lejeune, D., Lefèbvre, P., & Greenberg, P. E. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0140 · Cited by 35
Lin, J., Szukis, H., Sheehan, J. J., Alphs, L. D., Menges, B., Lingohr-Smith, M., & Benson, C. J. (2019) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20190001 · Cited by 28
“Use of health care resources by patients with treatmentresistant depression contributes significantly to the economic burden of the condition, which in the United States has been estimated to range from $29 to $48 billion annually (7).”
BackgroundResultMason, N. L., & Kuypers, K. P. C. (2018) · Journal of Psychedelic Studies · doi:10.1556/2054.2018.006 · Cited by 34
Yang, K., Yu, J., Nong, K., Wang, Y., Niu, A., Chen, W., Dong, J., & Wang, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00739 · Cited by 28
Benitez, J., Cool, C. L., & Scotti, D. J. (2018) · Personalized Medicine · doi:10.2217/pme-2018-0074 · Cited by 29
Keeping up with the clinical advances: depression
Ragguett, R.-M., Tamura, J. K., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852919001159 · Cited by 27
Zandi, P., Wang, Y.-H., Patel, P., Katzelnick, D., Turvey, C., Wright, J. H., Ajilore, O., Coryell, W., Schneck, C. D., Guille, C., et al. (2020) · Psychiatric Services · doi:10.1176/appi.ps.201900481 · Cited by 26
Li, G., Zhang, L., DiBernardo, A., Wang, G., Sheehan, J. J., Lee, K., Reutfors, J., & Zhang, Q. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238843 · Cited by 29
“In 2012, the US societal economic burden of major depressive disorder was estimated at $188 billion, which exceeded the US societal burden of cancer ($131 billion) and diabetes ($173 billion) [4].”
BackgroundMadsen, K. B., Plana‐Ripoll, O., Musliner, K. L., Debost, J.-C., Petersen, L. V., & Munk‐Olsen, T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.042 · Cited by 33
Latest Advances in the Development of Eukaryotic Vaults as Targeted Drug Delivery Systems
Muñoz‐Juan, A., Carreño, A., Mendoza, R., & Corchero, J. L. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070300 · Cited by 30
“The current production of recombinant vault nanoparticles is mainly performed in Spodoptera frugiperda (Sf9) insect cells [59], where expression of only the MVP protein can direct the assembly of vault-like particles on polyribosomes [59,60].”
MethodAlario, A. A., & Niciu, M. J. (2021) · Chronic Stress · doi:10.1177/24705470211014210 · Cited by 26
Kious, B. M., Sabic, H., Sung, Y.-H., Kondo, D. G., & Renshaw, P. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000754 · Cited by 27
“Copyright © 2017 Wolters Kluwer H depression.(8) Accordingly, studies addressing the treatment of depression in women and the development of treatmentresistance are urgently needed.”
BackgroundMehta, S. H., Downar, J. H., Mulsant, B. H., Voineskos, D., Daskalakis, Z. J., Weissman, C. R., Vila‐Rodriguez, F., & Blumberger, D. M. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13412 · Cited by 33
Anesthetic Influence on Electroconvulsive Therapy: A Comprehensive Review
Dai, X., Zhang, R., Nan, D., Tang, L., & Zhao, B. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s467695 · Cited by 34
“3,4 Currently, conventional pharmacological interventions for various mental disorders are limited in their effectiveness, requiring time to take effect, and exhibiting relatively low rates of relief and efficacy.”
BackgroundPapp, M., Gruca, P., Łasoń, M., Niemczyk, M., & Willner, P. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119827889 · Cited by 31
“Treatment-resistant depression (TRD) represents a major burden on individuals and health services worldwide (Greden, 2001; Johnston et al., 2018; Mrazek et al., 2014).”
BackgroundShah, D., Allen, L., Zheng, W., Madhavan, S., Wei, W., LeMasters, T. J., & Sambamoorthi, U. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01029-2 · Cited by 27
Ahmed, H. H., Essam, R. M., El-Yamany, M. F., Ahmed, K. A., & El-Sahar, A. E. (2023) · Food & Function · doi:10.1039/d3fo02222f · Cited by 28
Fife, D., Reps, J., Cepeda, M. S., Stang, P., Blacketer, M., & Singh, J. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00707 · Cited by 22
Wang, Y., Wang, X., Lan, L., Guo, Z., Kan, F., Hu, D., Gai, C., & Zhang, Y. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03605-1 · Cited by 32
“According to reported data from the USA, the rates of disability are 29.4% [6], and the annual costs are $5481 and $4048 higher for TRD patients than for non-TRD patients, respectively, in health care and lost productivity [7].”
InfluentialRiesenberg, R. A., Yeung, P. P., Rekeda, L., Sachs, G. S., Kerolous, M., & Fava, M. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22m14643 · Cited by 30
Pradhan, B., Parikh, T., Makani, R. D., & Sahoo, M. (2015) · Depression Research and Treatment · doi:10.1155/2015/842817 · Cited by 32
Pedersen, E. R., Rubenstein, L. V., Kandrack, R., Danz, M., Belsher, B. E., Motala, A., Booth, M. J., Larkin, J., & Hempel, S. (2018) · Implementation Science · doi:10.1186/s13012-018-0788-8 · Cited by 28
Agboola, F., Atlas, S. J., Touchette, D. R., Fazioli, K., & Pearson, S. D. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.1.16 · Cited by 24
Rathod, S., Denee, T., Eva, J., Kerr, C., Jacobsen, N., Desai, M., Baldock, L., & Young, A. H. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.090 · Cited by 23
Corral, R. M., Alessandria, H., Baena, L. M. A., Ferro, E., Duque-Alarcón, X., Quarantini, L. C., Caldieraro, M. A., Cabrera, P., & KANEVSKY, G. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.812938 · Cited by 33
Fang, H., & Yang, Y. (2023) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2023.1119685 · Cited by 26
“Moreover, more than 30% of MDD patients are treatment-resistant, meaning they do not respond to medication or psychotherapy (Rush et al., 2006;Mrazek et al., 2014).”
BackgroundInkster, B., Zai, G. C., Lewis, G., & Miskowiak, K. W. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0270-z · Cited by 27
Gałecki, P., & Bliźniewska-Kowalska, K. M. (2019) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/115208 · Cited by 30
“The total direct and indirect costs for a patient with drug-resistant depression are 20,120 $, compared with 10,592 $ spent on a patient responding to treatment [27].”
BackgroundTranscranial direct current stimulation: considerations for research in adolescent depression
Lee, J. C., Lewis, C. P., Daskalakis, Z. J., & Croarkin, P. E. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00091 · Cited by 22
“Adolescent MDD can impact psychosocial development, education, and employability (12), costing society billions of dollars each year (13).”
BackgroundNikolin, S., Martin, D. M., Loo, C. K. A., Iacoviello, B. M., & Boonstra, T. W. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14656 · Cited by 28
Neuromodulation for major depressive disorder: innovative measures to capture efficacy and outcomes
Rabin, J. S., Davidson, B., Giacobbe, P., Hamani, C., Cohn, M., Illes, J., & Lipsman, N. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30187-5 · Cited by 24
Metadata
- Authors
- Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I.
- Affiliations
- Mayo Clinic (US)
- Venue
- Psychiatric Services
- Published
- 2014-08
- Volume
- 65
- Issue
- 8
- Pages
- 977-987
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2111118992
- Cited by
- 580
- References
- 80
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 37 · 2023: 76 · 2022: 62 · 2021: 78 · 2020: 64 · 2019: 66 · 2018: 49 · 2017: 28 · 2016: 23 · 2015: 19 · 2014: 3
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, economic burden, social burden, quality of life, health care costs, productivity loss, treatment response rate, suicide attempts, disease duration, major depressive disorder
- MeSH terms
- Major Depressive Disorder, Depressive Disorder, Major, Humans, Quality of Life, Cost of Illness, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.